nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

27.02.2019 | Original Article – Clinical Oncology

Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma

verfasst von: Xingyu Cheng, Han Yin, Juan Fu, Chunya Chen, Jianhong An, Jiexia Guan, Rong Duan, Hengming Li, Hong Shen

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Lung cancer prevalence with its high mortality rate is a trending topic globally. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The human gene TTN encoding for TITIN protein is known as major mutation gene in many types of tumor including NSCLC. However, it is still controversial that TTN is a cancer-associated candidate considering tumor heterogeneity and complex genetic structure. In-depth researches on correlation between TTN mutation and NSCLC are still limited and discussable.

Methods

Related somatic mutation profiles and attached clinical data were from The Cancer Genome Atlas (TCGA) lung project. Clinical relevance analysis of TTN mutation was evaluated using univariate analysis and a binary logistic regressive model. Survival analysis and screening of independent prognostic factors in mutation types were conducted by Cox proportional hazards models and Kaplan–Meier methods.

Results

Available data covering lung adenocarcinoma (n = 517) and lung squamous cell carcinoma (n = 492) were analyzed. TTN genetic mutations exhibited significant association with lung squamous cell carcinoma. Patients with lung squamous cell carcinoma possessed favorable overall survival benefits from TTN mutant type and both favorable overall survival and disease-free survival benefits from TTN/TP53 double mutation. For patients with lung squamous cell carcinoma, about 85% of subjects with TTN mutation harbored missense variations, which was an independent indicator of good prognosis.

Conclusions

Missense mutation of TTN may act as a beneficial role in lung squamous cell carcinoma, but not in lung adenocarcinoma.

Nur mit Berechtigung zugänglich

Ceyhan-Birsoy O et al (2013) Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. Neurology 81:1205–1214. https://doi.org/10.1212/WNL.0b013e3182a6ca62 CrossRefPubMedPubMedCentral

Deben C et al (2017) Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants. Tumour Biol J Int Soc Oncodev Biol Med. https://doi.org/10.1177/1010428317694327 CrossRef

Domingo E et al (2016) Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol 1:207–216. https://doi.org/10.1016/s2468-1253(16)30014-0 CrossRefPubMed

Herman DS et al (2012) Truncations of titin causing dilated cardiomyopathy. N Engl J Med 366:619–628. https://doi.org/10.1056/NEJMoa1110186 CrossRefPubMedPubMedCentral

Hofree M, Shen JP, Carter H, Gross A, Ideker T (2013) Network-based stratification of tumor mutations. Nat Methods 10:1108–1115. https://doi.org/10.1038/nmeth.2651 CrossRefPubMedPubMedCentral

Kim N, Hong Y, Kwon D, Yoon S (2013) Somatic mutaome profile in human cancer tissues. Genom Inform 11:239–244. https://doi.org/10.5808/gi.2013.11.4.239 CrossRef

Kim YA, Madan S, Przytycka TM (2017) WeSME: uncovering mutual exclusivity of cancer drivers and beyond. Bioinformatics (Oxf Engl) 33:814–821. https://doi.org/10.1093/bioinformatics/btw242 CrossRef

Labbe C et al (2017) Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer (Amst Neth) 111:23–29. https://doi.org/10.1016/j.lungcan.2017.06.014 CrossRef

Lawrence MS et al (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:214–218. https://doi.org/10.1038/nature12213 CrossRefPubMedPubMedCentral

Ma X et al (2016) Prognostic and predictive effect of TP53 mutations in patients with non-small cell lung cancer from adjuvant cisplatin-based therapy randomized trials: a LACE-bio pooled analysis. J Thorac Oncol Off Publ Int Assoc Study of Lung Cancer 11:850–861. https://doi.org/10.1016/j.jtho.2016.02.002 CrossRef

Maki-Nevala S et al (2016) Hot spot mutations in Finnish non-small cell lung cancers. Lung Cancer (Amst Neth) 99:102–110. https://doi.org/10.1016/j.lungcan.2016.06.024 CrossRef

McGowan M, Hoven AS, Lund-Iversen M, Solberg S, Helland A, Hirsch FR, Brustugun OT (2017) PIK3CA mutations as prognostic factor in squamous cell lung carcinoma. Lung Cancer (Amst Neth) 103:52–57. https://doi.org/10.1016/j.lungcan.2016.11.018 CrossRef

Minde DP, Anvarian Z, Rudiger SG, Maurice MM (2011) Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer? Mol Cancer 10:101. https://doi.org/10.1186/1476-4598-10-101 CrossRefPubMedPubMedCentral

Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T (1993) Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 85:2018–2023CrossRefPubMed

Molina-Vila MA et al (2014) Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res 20:4647–4659. https://doi.org/10.1158/1078-0432.ccr-13-2391 CrossRef

Rami-Porta R, Bolejack V, Giroux DJ, Chansky K, Crowley J, Asamura H, Goldstraw P (2014) The IASLC lung cancer staging project: the new database to inform the eighth edition of the TNM classification of lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 9:1618–1624. https://doi.org/10.1097/jto.0000000000000334 CrossRef

Schafer S, de Marvao A (2017) Titin-truncating variants affect heart function in disease cohorts and the general population. Nat Genet 49:46–53. https://doi.org/10.1038/ng.3719 CrossRef

Schmidt LH et al (2016) Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC. Lung Cancer (Amst Neth) 92:8–14. https://doi.org/10.1016/j.lungcan.2015.11.019 CrossRef

Seo JS et al (2012) The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22:2109–2119. https://doi.org/10.1101/gr.145144.112 CrossRefPubMedPubMedCentral

VanderLaan PA et al (2017) Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes. Lung Cancer (Amst Neth) 106:17–21. https://doi.org/10.1016/j.lungcan.2017.01.011 CrossRef

Watanabe H et al (2016) A rapid functional decline type of amyotrophic lateral sclerosis is linked to low expression of TTN. J Neurol Neurosurg Psychiatry 87:851–858. https://doi.org/10.1136/jnnp-2015-311541 CrossRef

Titel: Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma
verfasst von: Xingyu Cheng
Han Yin
Juan Fu
Chunya Chen
Jianhong An
Jiexia Guan
Rong Duan
Hengming Li
Hong Shen
Publikationsdatum: 27.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2019
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-019-02861-y

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma